EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • EGFR mutation

carboplatin • paclitaxel • pemetrexed • rulonilimab (F520)

over2years

A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL (clinicaltrials.gov)

P2, N=62, Not yet recruiting, Shandong New Time Pharmaceutical Co., LTD

over 2 years ago

New P2 trial

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

F007 (rituximab biosimilar) • rulonilimab (F520)

over3years

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). (clinicaltrials.gov)

P2, N=105, Not yet recruiting, Shandong New Time Pharmaceutical Co., LTD | Initiation date: Jul 2020 --> Nov 2020

over 3 years ago

Clinical • Trial initiation date

PD-L1 (Programmed death ligand 1)

rulonilimab (F520)

almost4years

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). (clinicaltrials.gov)

P2, N=105, Not yet recruiting, Shandong New Time Pharmaceutical Co., LTD

almost 4 years ago

Clinical • New P2 trial

PD-L1 (Programmed death ligand 1)

rulonilimab (F520)

4years

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 (clinicaltrials.gov)

P1, N=75, Recruiting, Shandong New Time Pharmaceutical Co., LTD | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Feb 2020 --> Feb 2021

4 years ago

Clinical • Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

rulonilimab (F520)